I think this is how it is. They foresee having the full

New Post Public Reply Private Reply Replies (1) Message Board
freegriff
I think this is how it is. They foresee having the full data package by eoy, having lympro boom, set, settled, in use, tested and looking true. Remember Geralds comments after july c4ct? That they expect to blow everyone away at the next c4ct (which is jan 28 2015 on c4ct website)? Well, if you ask me, the winter c4ct during football playoffs will be the best time for media events etc and to really show the baller data. We will accumulate the evidence and reveal it beforehand, but that will be the big show off point, jan and feb. Can you imagine being part of a 60 minutes segment, even for 5 minutes of a 20 minute story on concussions on pre superbowl sunday, having clips played over and over during week leading to game? I think we would be better served if we're not an OTC stock at that point. But I think they wonder if it makes more sense to use the biotech pump craziness that always occurs after christmas to tie in with media push, winter ct4c, other attention since thats heavy sports season period to get a better r/s scenario etc. By then, we will have a firmer foundation in other areas too like manf and elto and I really could see between fundamentals and the right media environment the ideal situation. I have no idea what the right decision is. All I know is I am in this company until I see them having shit data or being so wrong/blind that they have to dilute against their guidance.

I played college soccer, defense since I was 4, so I have taken years and years of repeated head abuse including two concussions and feel a little dimmer these days. I am curious myself if I have damage and my aging parents and the fact I may have to care for them (lest I surely inherit the Wind) make me very eager to get shit rolling on the alz/pd fronts. The pedigree of people involved in this company is great. The science makes some sense to me as a chem major and to my buddies in med school, as much as it can to a non specialist. It's a bet. A bet for a better life and the reward in assisting in that achievement.

I never bet the farm, but I have been duly rewarded and lost my ass on companies like this before. Management is key. GC is a great writer and he's also probably impatient with his own success, building up some hype in his own mind because he wants it to be true and needs to communicate the value of that potential. It colors his writing, and explains why he writes so much. But I don't doubt his determination or the skill set of the team. Maybe they got assets for a song that won't sing. Assets in all areas of investment get pumped all the time. Sometimes shit doesn't pan out. But there is no indication this won't with a consistently growing management team and old school service minded science. There appears a stark difference between the officers here and officers in companies where I've lost my ass. We will see.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rebecca Rogers Tijerino Honored in Healthcare Staffing

Updated Category News Views 45

New Heights in Healthcare Staffing Leadership Let's talk about an industry giant making waves. Medical Solutions Chief Executive Officer Rebecca Rogers Tijerino has just snagged a spot on Staffing Industry Analysts' first-ever Healthcare Staffing 100 list. It's a long-overdue spotlight on one of the sharp minds shaking up the healthcare staffing landscape. This ain't just...

Continue Reading
PSG's Anna AI Wins Vizient's Innovative Tech Nod

Updated Category News Views 97

Hospital Hiring Gets a Tech Boost In the bustling world of healthcare recruitment, it's like trudging through quicksand with a time bomb strapped to your back. That's where PSG Global Solutions sauntered into the Las Vegas spotlight with Anna AI, their generative AI marvel that just snagged the Innovative Technology designation from Vizient. This ain’t your...

Continue Reading
Proterra Secures $680M in Fund 3, Exceeds Expectations

Updated Category News Views 65

Proterra's Bold Move Shakes the Market Alright, folks. You've got Proterra Investment Partners stepping up and showing its mettle with the close of its third private credit fund. Guess what? They pulled in $680 million, cruising past their $500 million target like a hot knife through butter. That's no small potatoes in the finance world, especially when you add up the...

Continue Reading
Truelink's Strategic Expansion: GES Acquires CSG Creative

Updated Category News Views 56

Truelink's Big Move in Creative Marketing I don't throw around the word 'synergy' lightly, but this Truelink Capital move has me grudgingly utter it. Picture this: GES, a big dog in event marketing, just grabbed CSG Creative, a firm with its teeth sunk deep into association and event organizer marketing. It sounds like the kind of match you only find lurking in the fancy...

Continue Reading
Pharmaceutical Navigator ASTHO's Podcast Earns Bronze Anthem Award

Updated Category News Views 80

An Award to Nod At: ASTHO's Public Health Triumph The world of public health isn't generally where you'd find shiny accolades flying around, but when they do, it's worth taking notice. Recently, ASTHO’s podcast, the Public Health Review Morning Edition, snagged a Bronze Anthem Award. Sure, it isn't the gold trophy, but in this high-stakes arena, any medal's a feat! More...

Continue Reading
Ameren Ups Earnings Guidance Amid Strong Q3 2026

Updated Category News Views 102

A Boost in Earnings During a Hot Third Quarter Ameren Corporation, ticker NYSE: AEE, just released its third quarter 2026 results, and things are looking brighter on the earnings front. We're seeing a bump here, with GAAP diluted EPS hitting $2.42 compared to the $2.35 from the year before. Adjusted EPS follows suit, jumping from $2.17 in 2025 to that same $2.42 mark now....

Continue Reading
Endava Faces Class Action for Securities Violation

Updated Category News Views 78

Endava's Legal Storm Clouds Gather Well, well, looks like Endava plc (NYSE: DAVA) has found itself knee-deep in a legal quagmire, thanks to some not-so-transparent financial antics. Investors are up in arms, and the fine folks at DJS Law Group are stepping in, filing a class action lawsuit against Endava for overstating their financial health. They allege that Endava made...

Continue Reading
Asper.ai's Big Move: Grows Europe Footprint in RGM

Updated Category News Views 75

Asper.ai Eyes RGM Market with Strategic Acquisition Folks, Asper.ai's latest move is a bold stride into a crowded field, snatching up the expertise of Pricing One to fuel its revenue growth management (RGM) platform. Now, if you're scratching your head over what all this entails, picture it this way: it's like arming a seasoned sales team with cutting-edge tech. This...

Continue Reading
NSING's Bluetooth Milestone: A Signal for Investors

Updated Category News Views 150

The Bluetooth Bonanza: NSING Technologies' Big Win Amidst the bustling lanes of the semiconductor sector, NSING Technologies just threw down a whopper of an announcement—over 250 million Bluetooth chips shipped, all well-knitted with Ceva's technology. This isn’t just another milestone; it's a clarion call for anyone keeping an eye on the evolving landscape of...

Continue Reading
Freddy's Rolls Out Value Menu in Test Markets

Updated Category News Views 83

Freddy's Value Experiment Spices Up the Fast-Food Game Wichita’s own Freddy's Frozen Custard & Steakburgers is stepping into the ring with a fresh strategy: an Everyday Value Menu. It’s quite the play, and it’s only going down in select markets. I gotta admit, the move is intriguing. These guys are taking a calculated shot, testing the waters in Arizona, Colorado,...

Continue Reading

Top 5 Most Recently Viewed Articles

Plymouth Industrial REIT Makes Strategic Acquisitions in Key Cities

Updated Category News Views 105

Plymouth Industrial REIT Expands Its Industrial Portfolio Today marks an exciting milestone for Plymouth Industrial REIT, Inc. (NYSE: PLYM), a key player in the real estate investment sector. The company has successfully acquired additional properties, strengthening its footprint in the industrial real estate market. New Acquisitions in Cincinnati Plymouth Industrial REIT...

Continue Reading
Monroe Capital's Strategic Move to Boost JobNimbus Acquisition

Updated Category News Views 307

Monroe Capital's Key Support for JobNimbus Acquisition Monroe Capital LLC has recently announced its role as the sole lead arranger and administrative agent for a significant senior credit facility. This funding is aimed at supporting the acquisition of JobNimbus by Sumeru Equity Partners, showcasing Monroe's commitment to backing innovative businesses in the technology...

Continue Reading
Celebrating Rita Gupta: A Leading Innovator in Technology

Updated Category News Views 679

Rita Gupta Honored for Innovation in Memory and Storage Award honors trailblazing innovators leading the future of memory and storage Future of Memory and Storage (FMS) proudly announces Rita Gupta, Fellow in the Server System Architecture team at AMD, as the recipient of the 2025 SuperWomen of FMS Award sponsored by Hammerspace and Pure Storage. This prestigious honor...

Continue Reading
Spanish Stock Market Shows Resilience with IBEX 35 Rise

Updated Category News Views 419

Spanish Market Overview The Spanish stock market showed positive momentum recently, with the IBEX 35 index recording a modest gain of 0.19%. This uptick reflects a notable shift in investor sentiment across various sectors, leading to an overall increase in share prices. Leading Sectors Driving Growth The rise in the IBEX 35 was attributed primarily to strong performances...

Continue Reading
Retail Opportunity Investments Corp. Achieves New Stock Milestones

Updated Category News Views 29

Record-Setting Performance for Retail Opportunity Investments Corp. Retail Opportunity Investments Corp. (NASDAQ: ROIC) has recently reached a remarkable milestone, with its stock price climbing to a 52-week high of $17.01. This achievement reflects a considerable growth period for the company, showcasing not only robust financial performance but also heightened investor...

Continue Reading